APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173968240330 December 2025195 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Attenuated Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Attenuated Vaccine include Changchun BCHT Biotechnology Co.,Ltd, Shanghai Rongsheng Biotech, Sanofi, Johnson & Johnson, Merck & Co., Pfizer Inc, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd. and Green Cross Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Attenuated Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attenuated Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attenuated Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Attenuated Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Attenuated Vaccine Segment by Company

Changchun BCHT Biotechnology Co.,Ltd

Shanghai Rongsheng Biotech

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer Inc

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Green Cross Corporation

CSL Limited

Biken

Astellas Pharma

Attenuated Vaccine Segment by Type

Bacterial Vaccine

Viral Vaccine

Attenuated Vaccine Segment by Application

Hospital

Clinic

Others

Attenuated Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attenuated Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Attenuated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Attenuated Vaccine Industry Trends Table 2. Attenuated Vaccine Industry Drivers Table 3. Attenuated Vaccine Industry Opportunities and Challenges Table 4. Attenuated Vaccine Industry Restraints Table 5. Global Attenuated Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Attenuated Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Attenuated Vaccine Sales Market Share by Manufacturers Table 9. Global Attenuated Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Attenuated Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Attenuated Vaccine Manufacturers, Product Type & Application Table 13. Global Attenuated Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Attenuated Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Bacterial Vaccine Table 17. Major Manufacturers of Viral Vaccine Table 18. Global Attenuated Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Attenuated Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Attenuated Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Attenuated Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Attenuated Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Attenuated Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Attenuated Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Attenuated Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Others Table 31. Global Attenuated Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 33. Global Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 34. Global Attenuated Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Attenuated Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Attenuated Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Attenuated Vaccine Revenue by Application (2021-2026) & (K Units) Table 38. Global Attenuated Vaccine Revenue by Application (2027-2032) & (K Units) Table 39. Global Attenuated Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Attenuated Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Attenuated Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Attenuated Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Attenuated Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 48. North America Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 49. Europe Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 51. Europe Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Attenuated Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Attenuated Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Attenuated Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Attenuated Vaccine Revenue Market Share by Region (2027-2032) Table 63. Changchun BCHT Biotechnology Co.,Ltd Company Information Table 64. Changchun BCHT Biotechnology Co.,Ltd Business Overview Table 65. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio Table 67. Changchun BCHT Biotechnology Co.,Ltd Recent Development Table 68. Shanghai Rongsheng Biotech Company Information Table 69. Shanghai Rongsheng Biotech Business Overview Table 70. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio Table 72. Shanghai Rongsheng Biotech Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Attenuated Vaccine Product Portfolio Table 77. Sanofi Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Johnson & Johnson Attenuated Vaccine Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Merck & Co. Company Information Table 84. Merck & Co. Business Overview Table 85. Merck & Co. Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Merck & Co. Attenuated Vaccine Product Portfolio Table 87. Merck & Co. Recent Development Table 88. Pfizer Inc Company Information Table 89. Pfizer Inc Business Overview Table 90. Pfizer Inc Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Pfizer Inc Attenuated Vaccine Product Portfolio Table 92. Pfizer Inc Recent Development Table 93. GlaxoSmithKline plc Company Information Table 94. GlaxoSmithKline plc Business Overview Table 95. GlaxoSmithKline plc Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. GlaxoSmithKline plc Attenuated Vaccine Product Portfolio Table 97. GlaxoSmithKline plc Recent Development Table 98. Serum Institute of India Pvt. Ltd. Company Information Table 99. Serum Institute of India Pvt. Ltd. Business Overview Table 100. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio Table 102. Serum Institute of India Pvt. Ltd. Recent Development Table 103. Green Cross Corporation Company Information Table 104. Green Cross Corporation Business Overview Table 105. Green Cross Corporation Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Green Cross Corporation Attenuated Vaccine Product Portfolio Table 107. Green Cross Corporation Recent Development Table 108. CSL Limited Company Information Table 109. CSL Limited Business Overview Table 110. CSL Limited Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. CSL Limited Attenuated Vaccine Product Portfolio Table 112. CSL Limited Recent Development Table 113. Biken Company Information Table 114. Biken Business Overview Table 115. Biken Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Biken Attenuated Vaccine Product Portfolio Table 117. Biken Recent Development Table 118. Astellas Pharma Company Information Table 119. Astellas Pharma Business Overview Table 120. Astellas Pharma Attenuated Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Astellas Pharma Attenuated Vaccine Product Portfolio Table 122. Astellas Pharma Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Attenuated Vaccine Distributors List Table 126. Attenuated Vaccine Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Attenuated Vaccine Product Image Figure 2. Global Attenuated Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Attenuated Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Attenuated Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Bacterial Vaccine Image Figure 9. Viral Vaccine Image Figure 10. Global Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Attenuated Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Attenuated Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Attenuated Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Attenuated Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Attenuated Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Attenuated Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Attenuated Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Attenuated Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Attenuated Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Attenuated Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Attenuated Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Attenuated Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Attenuated Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Attenuated Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial Vaccine
  • Viral Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Changchun BCHT Biotechnology Co.,Ltd
  • Shanghai Rongsheng Biotech
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Green Cross Corporation
  • CSL Limited
  • Biken
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Attenuated Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Attenuated Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Attenuated Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Attenuated Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Attenuated Vaccine Market Dynamics
  1. 2.1 Attenuated Vaccine Industry Trends
  2. 2.2 Attenuated Vaccine Industry Drivers
  3. 2.3 Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine Industry Restraints
3 Attenuated Vaccine Market by Manufacturers
  1. 3.1 Global Attenuated Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Attenuated Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Attenuated Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Attenuated Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Attenuated Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Attenuated Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Attenuated Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Attenuated Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Attenuated Vaccine Tier 1, Tier 2, and Tier 3
4 Attenuated Vaccine Market by Type
  1. 4.1 Attenuated Vaccine Type Introduction
  2. 4.1.1 Bacterial Vaccine
  3. 4.1.2 Viral Vaccine
  4. 4.2 Global Attenuated Vaccine Sales by Type
  5. 4.2.1 Global Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attenuated Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Attenuated Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Attenuated Vaccine Revenue by Type
  9. 4.3.1 Global Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Attenuated Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Attenuated Vaccine Revenue Market Share by Type (2021-2032)
5 Attenuated Vaccine Market by Application
  1. 5.1 Attenuated Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Attenuated Vaccine Sales by Application
  6. 5.2.1 Global Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attenuated Vaccine Sales by Application (2021-2032)
  8. 5.2.3 Global Attenuated Vaccine Sales Market Share by Application (2021-2032)
  9. 5.3 Global Attenuated Vaccine Revenue by Application
  10. 5.3.1 Global Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Attenuated Vaccine Revenue by Application (2021-2032)
  12. 5.3.3 Global Attenuated Vaccine Revenue Market Share by Application (2021-2032)
6 Global Attenuated Vaccine Sales by Region
  1. 6.1 Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attenuated Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Attenuated Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Attenuated Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Attenuated Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Attenuated Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Attenuated Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Attenuated Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Attenuated Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Attenuated Vaccine Revenue by Region
  1. 7.1 Global Attenuated Vaccine Revenue by Region
  2. 7.1.1 Global Attenuated Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Attenuated Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Attenuated Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Attenuated Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Attenuated Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Attenuated Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Attenuated Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Attenuated Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Attenuated Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun BCHT Biotechnology Co.,Ltd
  2. 8.1.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
  3. 8.1.2 Changchun BCHT Biotechnology Co.,Ltd Business Overview
  4. 8.1.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio
  6. 8.1.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
  7. 8.2 Shanghai Rongsheng Biotech
  8. 8.2.1 Shanghai Rongsheng Biotech Company Information
  9. 8.2.2 Shanghai Rongsheng Biotech Business Overview
  10. 8.2.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio
  12. 8.2.5 Shanghai Rongsheng Biotech Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Attenuated Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Attenuated Vaccine Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Merck & Co.
  26. 8.5.1 Merck & Co. Company Information
  27. 8.5.2 Merck & Co. Business Overview
  28. 8.5.3 Merck & Co. Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co. Attenuated Vaccine Product Portfolio
  30. 8.5.5 Merck & Co. Recent Developments
  31. 8.6 Pfizer Inc
  32. 8.6.1 Pfizer Inc Company Information
  33. 8.6.2 Pfizer Inc Business Overview
  34. 8.6.3 Pfizer Inc Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Inc Attenuated Vaccine Product Portfolio
  36. 8.6.5 Pfizer Inc Recent Developments
  37. 8.7 GlaxoSmithKline plc
  38. 8.7.1 GlaxoSmithKline plc Company Information
  39. 8.7.2 GlaxoSmithKline plc Business Overview
  40. 8.7.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc Recent Developments
  43. 8.8 Serum Institute of India Pvt. Ltd.
  44. 8.8.1 Serum Institute of India Pvt. Ltd. Company Information
  45. 8.8.2 Serum Institute of India Pvt. Ltd. Business Overview
  46. 8.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio
  48. 8.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
  49. 8.9 Green Cross Corporation
  50. 8.9.1 Green Cross Corporation Company Information
  51. 8.9.2 Green Cross Corporation Business Overview
  52. 8.9.3 Green Cross Corporation Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Green Cross Corporation Attenuated Vaccine Product Portfolio
  54. 8.9.5 Green Cross Corporation Recent Developments
  55. 8.10 CSL Limited
  56. 8.10.1 CSL Limited Company Information
  57. 8.10.2 CSL Limited Business Overview
  58. 8.10.3 CSL Limited Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 CSL Limited Attenuated Vaccine Product Portfolio
  60. 8.10.5 CSL Limited Recent Developments
  61. 8.11 Biken
  62. 8.11.1 Biken Company Information
  63. 8.11.2 Biken Business Overview
  64. 8.11.3 Biken Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biken Attenuated Vaccine Product Portfolio
  66. 8.11.5 Biken Recent Developments
  67. 8.12 Astellas Pharma
  68. 8.12.1 Astellas Pharma Company Information
  69. 8.12.2 Astellas Pharma Business Overview
  70. 8.12.3 Astellas Pharma Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma Attenuated Vaccine Product Portfolio
  72. 8.12.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Attenuated Vaccine Value Chain Analysis
  2. 9.1.1 Attenuated Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Attenuated Vaccine Production Mode & Process
  6. 9.2 Attenuated Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Attenuated Vaccine Distributors
  9. 9.2.3 Attenuated Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst